TX-SONAR
10.6.2024 15:01:28 CEST | Business Wire | Press release
Sonar, the leader in Clean Code solutions, today announced the expansion of its collaboration with Amazon Web Services (AWS) to help enterprises achieve high-quality code that is clean. SonarCloud, Sonar’s SaaS offering, will be available as an integration with Amazon CodeCatalyst, a unified software development service. Additionally, SonarCloud is now certified by the AWS Foundational Technical Review (FTR) – a set of guidelines to reduce risks around security, reliability, and operational excellence, as defined by the AWS Well-Architected Framework.
“With SonarCloud we enabled our engineering teams to drive consistent code quality and standards across the whole organization. The easy integration into our development toolchain and the simple UI allow us to scale fast and without any issues. The wide adoption and the excellent customer support help you overcome any difficulties,” said Andre Ostermeier, Lead Solutions Architect at Relayr. “Besides that, SonarCloud is an excellent tool to drive Engineering KPIs and should not be underestimated by IT leaders.”
SonarCloud and Amazon CodeCatalyst: Improving Development Processes
Amazon CodeCatalyst features blueprint capabilities that allow customers to automatically set up everything they need to start a new software development project, including continuous integration and delivery (CI/CD) pipelines, deployable code, issue tracking, and fully configured AWS services.
“Customers building apps need to release code early and often, and with solid DevOps practices and tools,” said Nicolas Pujol, ISV Partner Management Leader in EMEA, AWS. “Sonar has done a great job giving developers and DevOps leaders solutions to be more productive, and we’re excited to collaborate to make these tools available to AWS customers.”
Amazon CodeCatalyst paired with Sonar’s unique Clean as You Code approach, delivered through SonarCloud, empowers developers to spend more time writing innovative code and less time managing local development environments. With SonarCloud integrated into Amazon CodeCatalyst CI/CD workflows, development teams can more easily ensure that only clean code will be added to their code base, improving the overall quality of the code written.
Sonar Puts Customer Experience First
Sonar achieved the AWS Foundational Technical Review (FTR) certification by demonstrating that SonarCloud meets best practices critical for a customer’s success. SonarCloud allows for shared expectations across teams rooted in clean code practices, automates code quality checks, and provides extensive feedback for issue resolution.
Sonar’s Clean as You Code Approach
The Clean as You Code approach enables developers and organizations to improve development velocity, code quality, and code security. This simple yet powerful methodology progressively improves the overall quality of the entire codebase as the code is written, with minimal cost and effort. Clean as You Code puts developers in the driver's seat where they take full ownership of the quality of the code they write.
“An increasing number of developers are writing code and building apps in the cloud. We created SonarCloud to provide these developers an easy way to achieve a state of Clean Code, designing a tool that seamlessly integrates with DevOps platforms,” said Fabrice Bellingard, VP of Products at Sonar. “Our growing collaboration with AWS will help more cloud-based development teams create high-quality code with our unique Clean as You Code methodology.”
Today, SonarCloud has over 100,000 active users. The solution has helped a wide range of organizations clean over 2.5 billion lines of code. SonarCloud is free to use on open-source projects. To learn more about SonarCloud, visit here.
About Sonar
Sonar's Clean Code solutions, SonarQube, SonarCloud, and SonarLint, help developers prevent code quality and security issues from ever reaching production. Sonar analyzes all code, regardless of who writes it—your internal team or genAI—resulting in more secure, reliable, and maintainable software. Rooted in the open source community, Sonar’s solutions support over 30 programming languages, frameworks, and infrastructure technologies. Today, Sonar is used by 7M+ developers and 400K organizations worldwide, including the DoD, Microsoft, NASA, MasterCard, Siemens, and T-Mobile.
To learn more about Sonar, please visit: https://www.sonarsource.com/products/all/
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240610167595/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release
Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release
Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom